ST. LOUIS--(BUSINESS WIRE)--Geneoscopy Inc., a life sciences company focused on developing diagnostic tests for gastrointestinal health, today announced that Chief Executive Officer and Co-founder Andrew Barnell, MBA, will be presenting at the Morgan Stanley Global Healthcare Conference in New York, NY, on Monday, Sept. 11, at 2:15 p.m. Eastern Time.
Geneoscopy’s research and development efforts come at a critical time when 60-70 million Americans suffer from gastrointestinal (GI) diseases, including colorectal cancer (CRC) and inflammatory bowel disease (IBD). Many Americans do not get screened for CRC—often due to a lack of access or avoidance of invasive options like colonoscopies, resulting in increased incidence and mortality rates.
In addition, a recent study found that nearly 1 in 100 Americans suffer from IBD, with an estimated 2.39 million diagnosed. Although many IBD therapies are available and in development, clinicians and patients lack effective tools for therapy selection and monitoring to help ensure patients benefit from prescribed therapies.
To address these challenges, Geneoscopy is leveraging its novel platform technology to develop noninvasive diagnostic and precision medicine tools for GI diseases.
“We are pleased to be presenting at Morgan Stanley’s Annual Global Healthcare Conference to share the promising market opportunities for our proprietary RNA biomarker platform and high-value diagnostic tests,” said Andrew Barnell, CEO and Co-founder of Geneoscopy. “Our mission to transform gastrointestinal health begins by addressing the pressing need to expand access to more convenient and accurate screening options for CRC. And we believe that our pipeline of tests will enable a precision medicine approach to GI disease management and treatment, bringing value to healthcare stakeholders, most importantly, patients.”
Geneoscopy’s noninvasive, multi-target, stool RNA (mt-sRNA) colorectal cancer screening test received U.S. Food and Drug Administration’s (FDA) Breakthrough Device designation in 2020 and has been submitted to the FDA for Premarket Approval (PMA). This at-home screening test is designed to detect high-risk precancerous lesions (advanced adenomas) and CRC in average-risk individuals. In its pivotal CRC-PREVENT clinical trial, the test demonstrated 94% sensitivity for CRC and 46% sensitivity for advanced adenomas. These results are the highest reported for any noninvasive CRC screening test in any prospective registrational clinical study completed to date.
About Geneoscopy, Inc.
Geneoscopy Inc. is a life sciences company focused on developing diagnostic tests for gastrointestinal health. Leveraging its proprietary, patented stool-derived eukaryotic RNA (seRNA) biomarker platform, Geneoscopy’s mission is to empower patients and providers to transform gastrointestinal health through innovative diagnostics. Beyond colorectal cancer screening, Geneoscopy is developing tests for diagnosis, treatment selection, and therapy monitoring in other disease areas in partnership with leading universities and biopharmaceutical companies. For more information, visit www.geneoscopy.com and follow the company on LinkedIn.
Geneoscopy Inc. Forward-Looking Statements
This release includes information about Geneoscopy’s future plans concerning its noninvasive molecular test that can detect colorectal cancer and precancerous adenomas, which constitute forward-looking statements. These forward-looking statements are based on the Company’s reasonable estimates of future results or trends. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict, many of which are outside the Company’s control. Geneoscopy’s actual results and financial condition may differ materially from those in the forward-looking statements. Although the Company believes its business plans and objectives reflected in or suggested by these forward-looking statements are reasonable, such plans or objectives may not be achieved. The actual results may differ substantially from the projected result.